Drugs & Targets FDA approves Truxima as biosimilar to Rituxan for non-Hodgkin’s lymphoma November 30, 2018Vol.44 No.44
Drugs & TargetsFree Ziopharm Oncology announces Immuno-oncology Clinical Supply Agreement with Regeneron to evaluate combination therapy for brain cancer November 16, 2018Vol.44 No.43
Drugs & TargetsFree Immunomedics expands clinical collaboration with AstraZeneca to include metastatic NSCLC November 16, 2018Vol.44 No.43
Drugs & TargetsFree FDA grants priority review for Tecentriq + Abraxane for metastatic triple-negative breast cancer November 16, 2018Vol.44 No.43
Drugs & TargetsFree CHMP gives positive opinion for Kisqali combination therapy for all women with HR+/HER2- locally advanced or metastatic breast cancer November 16, 2018Vol.44 No.43
Drugs & TargetsFree FDA accepts novel clinical trial endpoint in approving Erleada for prostate cancer November 16, 2018Vol.44 No.43
Drugs & TargetsFree Using review pilot program, FDA takes two weeks to approve first-line treatment for peripheral T-cell lymphoma November 16, 2018Vol.44 No.43
Drugs & Targets FDA approves Empliciti + pomalidomide and dexamethasone for multiple myeloma November 09, 2018Vol.44 No.42
Drugs & Targets FDA grants Fast Track to selinexor for diffuse large B-cell lymphoma November 09, 2018Vol.44 No.42
Drugs & Targets Seattle Genetics submits sBLA for ADCETRIS in frontline treatment of CD30-expressing peripheral T-cell lymphomas November 09, 2018Vol.44 No.42
